According to an evaluation published in The New England Journal of Medicine, messenger-RNA vaccines given to young children between the ages of 6 and 11 are safe, effective, and comparable to those given to adults.
“Two 50-μg doses of mRNA-1273 vaccine were found to be safe and effective in inducing an immune response and preventing COVID-19 in children aged 6 to 11 years; The study, published on May 26, noted that these responses were not less common in young adults.
According to the study authors, immunization of children to prevent COVID-19 is an urgent public health need. The study claimed in the background, “The safety, immunogenicity and efficacy of the mRNA-1273 (code name for Moderna Vaccine) vaccine in children 6 to 11 years of age are unknown.”
The study authors stated that “our trial demonstrated the efficacy of the mRNA-1273 vaccine when delta was the dominant circulating variant and provided preliminary results indicating that the mRNA-1273 vaccine in children elicited neutralizing antibody responses against delta.” are similar to those observed in the post-booster vaccination type in adults”.
These findings suggest that this vaccine confers a protective benefit to children against various forms of anxiety, he said.
Although the highest risk of illness and death from COVID-19 occurs in older adults and in the underlying coexisting population, children are at risk of severe acute respiratory syndrome infection, which can lead to hospitalization, life-threatening complications, and complications from severe COVID-19. There may be related consequences. -Assistant intervention, and death.
The burden of COVID-19 in children extends to social issues such as school interruptions and other disruptions in life, which can result in long-term consequences for academic development and well-being.
While the Indian vaccination campaign against COVID-19 has not used any mRNA or messenger-RNA based vaccine, the country is expected to soon get its indigenous vaccine made on the Pune-based mRNA platform. Genova Biopharmaceuticals, As of now, for the age group below 12 years, India Bharat Biotech’s Covaxin and Biologicals E’s Corbevax have been approved.
Efficacy after a single dose similar to that of adults
The findings of the latest study are consistent with those reported in other studies showing the effectiveness of the mRNA-1273 vaccine in reducing Covid-related hospital admissions during infusion of the delta variant and neutralizing variants including the omicron variant after vaccination. We do. Children and teenagers.
Read also | Government panel recommends use of Corbevax in children aged 5-12 years amid covid uptick
However, the study also faced several limitations.
“Due to the few cases of COVID-19 that occurred during the short, blinded phase of the trial, evaluation of the efficacy of mRNA-1273 after two injections was limited when the number of cases would be expected to be high; Nevertheless, the efficacy observed after a single injection is similar to the efficacy observed in adolescents and adults who have received mRNA-1273.
Although the trial was conducted to assess the safety of rare events, even rarer events were identified during the global distribution of COVID-19 vaccines; Thus, constant vigilance is necessary in monitoring the security, it suggests.
read all breaking news , today’s fresh news And IPL 2022 Live Updates Here.